Despite treatment of locally advanced rectal cancer relapses are frequent. Several attempts
to improve these results with therapy intensification have shown modest effect on disease
free survival (DFS) and overall survival (OS). Recent studies with addition of sorafenib and
cediranib revealed promising effect on tumor response with acceptable toxicity. Regorafenib
is a multi tyrosine kinase inhibitor (TKI) with a broad mechanism of action. Therefore this
trial investigates if similar results can be achieved as with sorafenib or cediranib.